These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38408701)

  • 21. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
    Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
    Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silent somatotroph pituitary adenomas: an update.
    Langlois F; Woltjer R; Cetas JS; Fleseriu M
    Pituitary; 2018 Apr; 21(2):194-202. PubMed ID: 29305680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives.
    Guaraldi F; Ambrosi F; Ricci C; Di Sciascio L; Asioli S
    Best Pract Res Clin Endocrinol Metab; 2024 May; 38(3):101894. PubMed ID: 38614953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
    Nasr C; Mason A; Mayberg M; Staugaitis SM; Asa SL
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4776-80. PubMed ID: 16968791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation.
    Kawakita S; Asa SL; Kovacs K
    J Endocrinol Invest; 1989; 12(7):443-48. PubMed ID: 2551950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas.
    Tang Y; Xie T; Guo Y; Liu S; Li C; Liu T; Zhao P; Yang L; Li Z; Yang H; Zhang X
    World Neurosurg; 2024 Feb; 182():e334-e343. PubMed ID: 38052365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
    Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
    Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mixed Sparsely Granulated Lactotroph and Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor Expands the Spectrum of Neuroendocrine Neoplasms in Ovarian Teratomas: the Role of Pituitary Neuroendocrine Cell Lineage Biomarkers.
    Hodgson A; Pakbaz S; Shenouda C; Francis JA; Mete O
    Endocr Pathol; 2020 Sep; 31(3):315-319. PubMed ID: 32632841
    [No Abstract]   [Full Text] [Related]  

  • 29. Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.
    Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2024 Sep; 83(9):708-721. PubMed ID: 38917431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas.
    Kato M; Inoshita N; Sugiyama T; Tani Y; Shichiri M; Sano T; Yamada S; Hirata Y
    Endocr J; 2012; 59(3):221-8. PubMed ID: 22200580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
    Larkin S; Reddy R; Karavitaki N; Cudlip S; Wass J; Ansorge O
    Eur J Endocrinol; 2013 Apr; 168(4):491-9. PubMed ID: 23288882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly.
    Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T
    Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suprasellar pituitary adenomas: a 10-year experience in a single tertiary medical center and a literature review.
    Zhu J; Wang Z; Zhang Y; Liu J; Li X; Deng K; Lu L; Yao Y
    Pituitary; 2020 Aug; 23(4):367-380. PubMed ID: 32378170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
    Buurman H; Saeger W
    Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study.
    Asa SL; Felix I; Kovacs K; Ramyar L
    Endocr Pathol; 1990 Dec; 1(4):228-235. PubMed ID: 32357614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
    Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
    Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of ghrelin in somatotroph and other types of pituitary adenomas.
    Wasko R; Jaskula M; Kotwicka M; Andrusiewicz M; Jankowska A; Liebert W; Sowinski J
    Neuro Endocrinol Lett; 2008 Dec; 29(6):929-38. PubMed ID: 19112387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
    Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
    PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.